NBTX Nanobiotix SA Forecast, Technical & Fundamental Analysis
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients... Show more
NBTX is expected to report earnings to fall 35.85% to -29 cents per share on September 30
Q2'26
Est.
$-0.29
Q4'25
Missed
by $0.06
Q2'25
Beat
by $0.23
Q4'24
Missed
by $0.39
Q2'24
Est.
$-0.51
The last earnings report on March 31 showed earnings per share of -45 cents, missing the estimate of -39 cents. With 11.63K shares outstanding, the current market capitalization sits at 2.02B.
A.I.dvisor indicates that over the last year, NBTX has been loosely correlated with CGEN. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if NBTX jumps, then CGEN could also see price increases.
NBTX in upward trend: price may ascend as a result of having broken its lower Bollinger Band on July 20, 2026
NBTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 41 cases where NBTX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 68 cases where NBTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on July 27, 2026. You may want to consider a long position or call options on NBTX as a result. In of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for NBTX just turned positive on July 22, 2026. Looking at past instances where NBTX's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
NBTX moved above its 50-day moving average on July 22, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for NBTX crossed bullishly above the 50-day moving average on July 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NBTX advanced for three days, in of 228 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 178 cases where NBTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NBTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (19.952). P/E Ratio (0.000) is within average values for comparable stocks, (38.269). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.516). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (56.818) is also within normal values, averaging (394.478).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Nanobiotix SA (NBTX) stock Forecast, Price Targets and Analysts Predictions - Tickeron.com
